Mukherjee Amrita, Cui Jinhong, Patel Pranali G, Bhagia Preeti, McCammon Susan D, Varambally Sooryanarayana, Shrestha Sadeep
Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA; Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, USA.
Biostatistics, University of Alabama at Birmingham School of Public Health, Birmingham, AL, USA.
Am J Otolaryngol. 2024 Nov-Dec;45(6):104444. doi: 10.1016/j.amjoto.2024.104444. Epub 2024 Jul 31.
Solid organ transplant recipients have an elevated risk of cancer following organ transplantation than the age-adjusted general population. We assessed incidence of head and neck squamous cell carcinoma (HNSCC) in heart, lung, and liver recipients.
BASIC PROCEDURES/METHODS: This retrospective cohort study included 124,966 patients from the United States Scientific Registry of Transplant Recipients (SRTR) database who received heart, lung, or liver transplantation between 1991 and 2010. Follow-up data were available until 2018. Patients with prevalent HNSCC at transplantation were excluded. Incident cases of HNSCC post organ transplantation were identified, and incidence rates (per 100,000 person-years) were reported by gender, race, organ type, year and age at organ transplantation.
The majority of patients received liver transplantation (58.64 %), followed by heart (28.64 %), and lung (12.72 %) transplantation. During follow-up, 4.14 % patients developed HNSCC. Overall incidence rate of HNSCC was 426.76 per 100,000 person-years. Male recipients had a higher HNSCC incidence rate than female recipients (571.8 and 177.0 per 100,000 person-years, respectively). Lung recipients had the highest overall HNSCC incidence rate (1273.6 per 100,000 person-years), followed by heart (644.2 per 100,000 person-years), and liver recipients (207.1 per 100,000 person-years). Overall, an increase in HNSCC incidence rate was observed with increase in age at organ transplantation. An increase in incidence rates of HNSCC over time was observed in lung recipients; however, incidence rates decreased over time in heart recipients.
Solid organ transplant recipients have a high incidence of HNSCC following organ transplantation, and the incidence varies by type of organ received.
实体器官移植受者在器官移植后患癌风险高于年龄匹配的普通人群。我们评估了心脏、肺和肝脏移植受者中头颈部鳞状细胞癌（HNSCC）的发病率。
基本程序/方法：这项回顾性队列研究纳入了1991年至2010年间在美国器官移植受者科学注册系统（SRTR）数据库中接受心脏、肺或肝脏移植的124,966名患者。随访数据截至2018年。排除移植时已患HNSCC的患者。确定器官移植后HNSCC的发病病例，并按性别、种族、器官类型、年份和器官移植时的年龄报告发病率（每10万人年）。
大多数患者接受肝脏移植（58.64%），其次是心脏移植（28.64%）和肺移植（12.72%）。随访期间，4.14%的患者发生了HNSCC。HNSCC的总体发病率为每10万人年426.76例。男性受者的HNSCC发病率高于女性受者（分别为每10万人年571.8例和177.0例）。肺移植受者的总体HNSCC发病率最高（每10万人年1273.6例），其次是心脏移植受者（每10万人年644.2例）和肝脏移植受者（每10万人年207.1例）。总体而言，随着器官移植时年龄的增加，HNSCC发病率呈上升趋势。肺移植受者中HNSCC发病率随时间增加；然而，心脏移植受者的发病率随时间下降。
实体器官移植受者在器官移植后HNSCC发病率较高，且发病率因所接受的器官类型而异。
